Objectives: Methods to quantify overdiagnosis of screen detected cancer have been developed, but methods for quantifying overdiagnosis of noncancer conditions (whether symptomatic or asymptomatic) have been lacking. We aimed to develop a methodological framework for quantifying overdiagnosis that may be used for asymptomatic or symptomatic conditions and used gestational diabetes mellitus as an example of how it may be applied.
Study Design And Setting: We identify two earlier definitions for overdiagnosis, a narrower prognosis-based definition and a wider utility-based definition. Building on the central importance of the concepts of prognostic information and clinical utility of a diagnosis, we consider the following questions: within a target population, do people found to have a disease using one diagnostic strategy but found not to have the disease using another diagnostic strategy (so called 'additional diagnoses'), have an increased risk of adverse clinical outcomes without treatment (prognosis evidence), and/or a decreased risk of adverse outcomes with treatment (utility evidence)?
Results: Using Causal Directed Acyclic Graphs and fair umpires, we illuminate the relationships between diagnostics strategies and the frequency of overdiagnosis. We then use the example of gestational diabetes mellitus to demonstrate how the Fair Umpire framework may be applied to estimate overdiagnosis.
Conclusion: Our framework may be used to quantify overdiagnosis in noncancer conditions (and in cancer conditions) and to guide further studies on this topic.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jclinepi.2022.04.022 | DOI Listing |
Stat Med
December 2024
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
Multicancer detection (MCD) tests use blood specimens to detect preclinical cancers. A major concern is overdiagnosis, the detection of preclinical cancer on screening that would not have developed into symptomatic cancer in the absence of screening. Because overdiagnosis can lead to unnecessary and harmful treatments, its quantification is important.
View Article and Find Full Text PDFJ Allergy Clin Immunol
January 2025
Institute for Immunity, Transplantation, and Infection, School of Medicine, Stanford University, Palo Alto, Calif; Department of Medicine, Center for Biomedical Informatics Research, School of Medicine, Stanford University, Palo Alto, Calif.
Radiol Med
September 2024
Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Purpose: This study quantifies the impact on budget and cost per health benefit of implementing digital breast tomosynthesis (DBT) in place of digital mammography (DM) for breast cancer screening among asymptomatic women in Italy.
Methods: A budget impact analysis and a cost consequence analysis were conducted using parameters from the MAITA project and literature. The study considered four scenarios for DBT implementation, i.
Br J Dermatol
November 2024
Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Background: Research suggests that a high proportion of melanoma in situ (MIS) may be overdiagnosed, potentially contributing to overtreatment, patient harm and inflated costs for individuals and healthcare systems. However, Australia-wide estimates of the magnitude of melanoma overdiagnosis are potentially outdated and there has been no estimation of the cost to the healthcare system.
Objectives: To estimate the magnitude and cost of overdiagnosed MIS and thin invasive melanomas in Australia.
J Biomed Inform
September 2024
Dedalus Healthcare, Antwerp, Belgium.
Background: An inherent difference exists between male and female bodies, the historical under-representation of females in clinical trials widened this gap in existing healthcare data. The fairness of clinical decision-support tools is at risk when developed based on biased data. This paper aims to quantitatively assess the gender bias in risk prediction models.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!